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Abstract
Background: Receptor associated protein (RAP) functions in the endoplasmic reticulum (ER) to assist in the maturation of
several membrane receptor proteins, including low density lipoprotein receptor-related protein (LRP) and lipoprotein
receptor 11 (SorLA/LR11). Previous studies in cell and mouse model systems have demonstrated that these proteins play
roles in the metabolism of the amyloid precursor protein (APP), including processes involved in the generation, catabolism
and deposition of b-amyloid (Ab) peptides.
Methodology/Principal Findings: Mice transgenic for mutant APPswe and mutant presenilin 1 (PS1dE9) were mated to
mice with homozygous deletion of RAP. Unexpectedly, mice that were homozygous null for RAP and transgenic for
APPswe/PS1dE9 showed high post-natal mortality, necessitating a shift in focus to examine the levels of amyloid deposition
in APPswe/PS1dE9 that were hemizygous null for RAP. Immunoblot analysis confirmed 50% reductions in the levels of RAP
with modest reductions in the levels of proteins dependent upon RAP for maturation [LRP trend towards a 20% reduction ;
SorLA/LR11 statistically significant 15% reduction (p,0.05)]. Changes in the levels of these proteins in the brains of
[APPswe/PS1dE9](+/2)/RAP(+/2) mice correlated with 30–40% increases in amyloid deposition by 9 months of age.
Conclusions/Significance: Partial reductions in the ER chaperone RAP enhance amyloid deposition in the APPswe/PS1dE9
model of Alzheimer amyloidosis. Partial reductions in RAP also affect the maturation of LRP and SorLA/LR11, which are each
involved in several different aspects of APP processing and Ab catabolism. Together, these findings suggest a central role
for RAP in Alzheimer amyloidogenesis.
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Introduction
The genetic alterations in APP and PS1 (and PS2) that cause early
onset familial Alzheimer’s disease (AD) are well characterized, as are
the consequences that disease-linked mutations in these proteins have
on the endoproteolytic processing of APP (for review see [1]).
However, the cause of sporadic AD is less well defined. The major
genetic risk factor for sporadic AD is the presence of the E4 allele of
the apolipoprotein E (Apo E) gene [2]. Polymorphisms in the LRP
and SorLA/LR11 genes have also been associated with increased risk
for Alzheimer’s disease [3,4]. However, there are studies that refute
the LRP finding [5–8].
LRP, a member of the low density lipoprotein (LDL) receptor
family, is a large, multifunctional endocytic receptor, highly
expressed in hepatocytes, fibroblasts, activated astrocytes, and
neurons(reviewedbyWillnow[9]). MatureLRPiscomposed oftwo
subunits, 515 kDa (a-chain) and 85 kDa (b-chain), which are
produced by proteolytic cleavage from a single polypeptide
precursor of 600 kDa in the trans-Golgi network [10]. Maturation
of LRP to the trans-Golgi network is partially dependent upon the
presence of LRP-receptor-associated protein (RAP), which binds to
LRP at multiple sites to block the receptor’s ability to interact with
its ligands [11]. Premature binding of LRP ligands to the receptor
interferes with maturation of LRP, and similar receptors, and with
translocation to the plasma membrane (reviewed by Willnow [12]).
LRP is a potentially important etiological agent for AD because
three proteins clearly involved in AD - APP, APOE, and a2-
macroglobulin (a2M), are ligands of LRP [for review see [13]].
Importantly, each of these proteins plays significant roles in the
production and metabolism of Ab peptide, the principal
component of amyloid plaques that characterize AD. LRP has
been found to bind to the amyloid precursor protein (APP) in a
manner that alters its trafficking and processing [14–18]. LRP-
deficient cells secrete less Ab and restoring LRP function
substantially increases Ab production [15]. One study has
reported reduced levels of LRP in the brains of AD patients
[19], but this finding has not been confirmed by others [20]. LRP
also appears to mediate the clearance of Ab that is bound to a2M
or ApoE[19,21–23]. It is, therefore, important to examine the role
of LRP in the pathogenesis of Alzheimer-type amyloidosis in
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large size of the LRP gene (.10 kb) makes production of
transgenic animals that express the whole protein difficult by
standard cDNA approaches. Zerbinatti et al. [24] reported that
overexpression of an LRP minireceptor in the PDAPP mouse
model of AD, resulted in increased levels of soluble Ab but did not
impact amyloid burden. Similarly, it is not possible to examine
adult animals that lack LRP because targeted deletion of the LRP
gene in mice leads to death of the embryo at day 13.5 [25].
However, the levels of functional LRP in the brain are regulated
by RAP. Unlike LRP, mice deficient in RAP are viable and have
normal lifespans because the maturation of LRP is only partially
dependent upon RAP; neurons of RAP KO mice show 75%
reductions in the levels of endoproteolytically processed, mature,
LRP [26]. It is noteworthy that expression of PS1 variants M146L
or L286V, which are linked to familial AD, also cause 40%
reductions in the levels of mature LRP in brain [27].
In the present study, we have utilized RAP KO mice crossed
with mice that co-express mutant APP (APPswe) and PS1
(PS1dE9) to examine how loss of RAP influences amyloid
deposition. This work, in part, is a repetition of a previous effort
by van Uden and colleagues in which RAP knockout mice were
crossed to the PDAPP model of AD amyloidosis [28]. However,
the present study differs from this previous work in a few
important ways, providing new insights into the mechanisms
involved. First, we determine the effects of partial loss of RAP on
amyloid deposition by examining mice with heterozygous deletion
of RAP. Second, we use mice that co-express mutant presenilin,
which has been shown in other studies to reduce the maturation of
LRP [27]. Third, we study mice that express the 695 isoform of
APP, which lacks a domain critical for interaction with LRP. Also,
we noted that methods described in the van Uden study indicated
that mice heterozygous for the APP transgene and heterozygous
for RAP [APP (+/2)/RAP(+/2)] were intercrossed to produce
the animals ultimately analyzed: APP transgene positive and
homozygous wild-type for RAP or homozygous null for RAP. A
possible flaw in this strategy is that some offspring could be
homozygous for the APP transgene (i.e. have two transgene alleles
instead of one). If transgene homozygous animals were, by chance,
over-represented in one of the RAP genotypes examined, then
there could be error in determining the contribution of RAP to
amyloid load. Thus, we repeated the study, using our APPswe/
PS1dE9 model of AD and RAP KO mice. For reasons that are not
clear, mice hemizygous for the APPswe/PS1dE9 transgenes and
homozygous null for RAP died at high frequency just after birth.
We therefore studied mice that were heterozygous null for RAP
and heterozygous for the APPswe/PS1dE9 transgenes. The partial
reduction in RAP led to very modest reductions in the levels of
mature LRP and SorLA/LR11 (,15–20% reductions of both)
with predictable 50% reductions in the levels of RAP. The changes
in the levels of these proteins correlated with 30–40% increases in
amyloid burden (assessed at 9 months of age). Our findings
indicate that RAP plays a focal role in the biology of amyloid
deposition either by regulating the maturation of proteins that
modulate APP processing and Ab metabolism, or by directly
modulating other yet to be defined aspects of amyloidogenesis.
Methods
Transgenic mice
The AD mouse model used in this study (APPswe/PS1dE9-Line
85) co-expresses a chimeric mouse/human APP695 harboring the
Swedish K670M/N671L mutations (Mo/HuAPPswe) and human
PS1with the exon-9 deletion mutation (PS1dE9). This model was
generated by co-injection of MoPrP.Xho expression plasmids for
each gene; the two transgenes co-integrated and segregate as a
single locus [29].
Mice with targeted-deletions of RAP (Strain B6, 129S-
Lrpap1
tm1Her ______) were purchased from the Jackson Laboratories
(stock # 002987; Bar Harbor, ME). These RAP knockout mice
[RAP(2/2)], which were congenic in the C57BL/6J strain, were
crossed to APPswe/PS1dE9 mice (Line 85), which were F2 hybrids
of C57BL/6J and C3H/HeJ. Progeny that were [APPswe/
PS1dE9](+/2)/RAP(+/2) were backcrossed to the congenic
RAP2/2 mice to hasten the production of mice that were
APPswe/PS1dE9 transgene positive and RAP null.
Tissue preparation, histology and amyloid burden
measurements
All procedures involving animals were approved by the Johns
Hopkins Institutional Animal Care and Use Committee. At the
specified age, animals were euthanized by overdose with ethyl
ether before the brains were removed and bisected sagittally. One
hemibrain was frozen on dry ice and stored at 280uC for
biochemical studies. The other hemibrain was immersion-fixed in
4% paraformaldehyde in phosphate-buffered saline (PBS pH 7.4).
Later, the fixed tissues were embedded in paraffin for silver
staining according to the Bielschowsky method [30] modified from
the Hirano method (detailed description in [31]).
Estimation of amyloid plaque loads was performed by counting
amyloid plaques in 6 sagittal sections through the hippocampus of
7 male [APPswe/PS1dE9](+/2)/RAP(+/2) mice and the 6
parental APPswe/PS1dE9-Line 85 male mice that were used in
the initial cross to RAP(2/2) females. Images of hippocampus
were captured by digital photography. The hippocampus was
defined and the amyloid deposits contained within were counted
separately by two people blinded to the genotype. The number of
plaques in each section were summed and then averaged for each
animal. Statistical analyses (2-tailed t-Test) were performed using
the average number of deposits in hippocampus for each animal as
a single data point.
Detection of high-molecular-weight aggregates of Ab
Amyloid burden was estimated biochemically by filter assay as
previously described [32]. Briefly, mouse hemi-forebrains (cerebel-
lum and brain stem removed) were homogenized by probe
sonication in 10 volumes of Tris-HCl buffered saline (20 mM
Tris-HCl, pH 8.0, 150 mM NaCl) with protease inhibitor. Six
parental Line 85 mice (all male) and 7 [APPswe/PS1dE9](+/2)/
RAP(+/2) mice (F1 and F2 offspring – all male) were used in this
study. Homogenates were centrifuged at 8006g for 5 min in a
microcentrifuge. The supernatant was adjusted to a final SDS
concentration of 1% and then passed through cellulose acetate
membranes, 0.2-mm pore size (OE66, Schleicher & Schuell, Keene,
NH), using a 96-well dot-blot apparatus under vacuum. Proteins
trapped by the filter were detected by immunostaining following
protocols used in immunoblotting with a rabbit polyclonal antibody
from Zymed, CA (Cat. #71–5800). Enhanced chemiluminescence
(ECL) signal was digitally captured with LAS-3000 imaging system,
and the intensity of the dots was quantified using Multi Gauge
software (Fujifilm, Japan). Two-tailed student t-test with equal
variance was used to estimate the difference between two groups.
Western blot analysis
Levels of RAP, LRP, SorLA/LR11 and APP were assessed by
western blot, using standard methods, as previously described [33].
Briefly, brains were homogenized as described above and then
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containing 100 mgo r5 0mg of total protein, were separated by
SDS-PAGE and transferred to nitrocellulose membranes. Blots
were incubated with rabbit polyclonal antibody 377 aLRP
(1:1000, gift of Dr. J. Herz, University of Texas Southwestern
Medical Center, Dallas, Texas, USA), rabbit polyclonal antibody
4109 aRAP (1:1000, also a gift of Dr. J. Herz), SorLA/
LR11antibody (1:1000; monoclonal, BD Biosciences, San Jose,
CA) or 6E10 Ab (1:5000, monoclonal, Signet Laboratories,
Dedham, MA, USA). Proteins bound to antibodies were revealed
by incubation with HRP conjugated secondary antibodies (KPL,
Gaithersburg, Maryland) and chemiluminescence. The signal was
captured and quantified using the LAS-3000 imaging system as
described above. The statistical methods of analysis are described
in the Figure Legends.
Results
RAP(2/2) mice, first described by Willinow et al. [26], were
obtained from the Jackson laboratories as congenic on the C57BL/
6J background. Animals were mated to APPswe/PS1dE9- Line 85
mice (B6C3/F2) background to produce an F1 generation of mice
thatwere[APP/PS1](+/2)/RAP(+/2),whichwethenbackcrossed
to RAP(2/2) mice in an attempt to produce mice that were [APP/
PS1](+/2)/RAP(2/2). However, we unexpectedly failed to obtain
weaning age mice that were [APP/PS1](+/2)/RAP(2/2)
(Table 1). The mating scheme used was expected to yield litters in
which 50% of the offspring were RAP(2/2), with roughly half of
these offspring also harboring the APPswe/PS1dE9 transgene.
Similarly 50% of the offspring should be RAP (+/2), with half of
these offspring also harboring the APPswe/PS1dE9 transgene.
However, weaning age offspring of the [APPswe/PS1dE9](+/2)/
RAP(2/2) genotype were present at far lower percentages than
expected; only 2 animalsof this genotype reached weaning age to be
identified and both of these died (of unknown causes) before
reaching 3 months of age. These results suggested that some type of
interaction between an activity of APPswe or PS1dE9 and the
absence of RAP leads to diminished survival of these animals.
Presently, we don’t understand the basis for this outcome.
Partial reduction in RAP levels increases amyloid burden
Because we were unable to produce [APPswe/PS1dE9](+/2)/
RAP(2/2) mice, we chose to compare the parental lines of
APPswe/PS1dE9 animals, which were wild-type with respect to
RAP, to F1 and F2 [APPswe/PS1dE9](+/2)/RAP(+/2) mice. By
multiple measures, we found that partial loss of RAP was associated
withincreased levels of amyloid deposition. Histologically, we found
that partial deletion of RAP increased the number of amyloid
deposits 1.5 fold in 9 month old mice (Figs. 1A and B). The average
number of silver stained plaques in the hippocampus of [APPswe/
PS1dE9](+/2)/RAP(+/2) mice was 13.5 as compared to 8.1 in the
parental line 85 mice. Statistical analyses of the data estimated the
difference in amyloid burden between the two genotypes has a low
probability of resulting from random chance (,0.05). To further
quantify the levels of aggregated b-amyloid in these mice, we used a
filter-trap assay [32] to demonstrate that the brains of mice
expressing APPswe/PS1dE9 with a partial loss of RAP contained
about twice as much high-molecular-weight Ab as controls (Fig. 2).
Homogenates of forebrain were serially diluted (2-fold) and filtered
through 0.2 mm cellulose acetate membrane, then immunoblotted
as described in Methods. We determined that the forebrain of
[APPswe/PS1dE9](+/2)/RAP(+/2) mice, as compared to
[APPswe/PS1dE9](+/2)/RAP(+/+) mice, contained about twice
as much Ab immunoreactivity that was retained by the filter
(p,0.025). Together, these findings provide evidence for higher
levels of amyloid in [APPswe/PS1dE9](+/2)/RAP(+/2) mice.
Partial reduction in RAP lowers the levels of SorLA/LR11
and LRP
Immunoblot analysis of tissue homogenates from the forebrain
of mice from the different genotypes was used to analyze the levels
of RAP, LRP, and SorLA/LR11 (Figs. 3A and B). As expected,
mice harboring one disabled RAP allele produced about 50% less
RAP protein (Figs. 3A and B). By contrast, the levels of LRP and
SorLA/LR11 did not show the same level of reduction (Figs. 3A
and B). On average, the levels of LRP were reduced 20%, but
variability between animals reduced statistical significance to only
a trend (p,0.20). The levels of SorLA/LR11, however, were less
variable and were measured as reduced on average by 15%
(p,0.05). Thus, the levels of both of these RAP-dependent
receptors were modestly reduced in mice partially deficient in
RAP. As previously reported in the literature [28], the brains of
mice lacking the expression of RAP showed marked reductions in
the levels of mature endoproteolytically processed LRP (85 KDa)
with higher levels of immature LRP (Fig. 4, lanes 6 and 7).
Surprisingly, the co-expression of PS1dE9 with partial reductions
in RAP did not lead to more robust reductions in the levels of
mature LRP (Fig. 4, lanes 2, 4, 5, 8, and 9 compared to lanes 1
and 3). Immunoblot analyses were also used to examine whether
reducing RAP levels had an effect on the levels of full-length
APPswe protein. Immunoblots with antibody 6E10, which
specifically recognizes the human Ab domain of the transgene
product, revealed similar amounts of full length APP in the brains
of mice with the two RAP genotypes (+/+ and +/2) (Fig. 5).
Together, we find that the partial loss of RAP modestly lowers the
levels of mature LRP and SorLA/LR11 in the brains of mice that
co-express APPswe/PS1dE9.
Discussion
The goal of the present investigation was to examine the roles of
RAP, and indirectly of LRP, on amyloidogenesis by reducing the
Table 1. Genotypes of offsprings between crosses of APPswe/PS1dE9(+)/RAP(+/2) mice and RAP (2/2) mice.
Genotype Expected Frequency Number of Offspring Observed Frequency
APPswe/PS1dE9(+)/RAP(+/2) 25% 23 41.0%
APPswe/PS1dE9(+)/RAP(2/2) 25% 2* 3.5%
RAP(+/2) 25% 21 37.5%
RAP(2/2) 25% 10 17.8%
*Both animals died before 3 months of age.
doi:10.1371/journal.pone.0003159.t001
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expressed APPswe/PS1dE9 in a RAP null background, we focused
our analysis on mice with only partial reductions of RAP, finding
that partial reduction increased the rate of Ab deposition by 1.5 to
2-fold. By our estimates, 50% reductions in the level of RAP cause
15–20% reductions in the levels of mature LRP and SorLA/
LR11. We expected that mice co-expressing mutant PS1dE9 with
partial reductions of RAP would exhibit larger affects on LRP
maturation because mice that are wild-type for RAP and
transgenic for PS1-M146L or L286V show 40% reductions in
the levels of mature LRP [27]. However, we did not observe an
obvious effect of PS1dE9 expression on LRP processing. Thus, the
strongest correlate to increased Ab deposition in this experiment is
the 50% reduction in RAP levels.
A caveat of our study is that the [APPswe/PS1dE9](+/2)/
RAP+/2 mice and the [APPswe/PS1dE9](+/2)/RAP(+/+) mice
they were compared to were of a slightly different genetic
background. The RAP knockout mice were congenic on the
C57BL/6J background while the parental APPswe/PS1dE9 mice
were hybrids of C57BL/6J and C3H/HeJ (maintained by crosses
of transgenic males to F1 hybrids of the 2 strains purchased from
Jackson Laboratory). In prior studies of mice that harbor the
APPswe and mutant PS1 transgene constructs utilized here, we
have noted that transfer of the transgene from the hybrid
background to C57BL/6J mice modestly delays the onset of
amyloid deposition to lower amyloid loads at younger ages [34].
Therefore, we have confidence that the increased amyloid burden
seen in first generation offspring of APPswe/PS1dE9 mice6RAP
knockout mice is due to the partial loss of RAP and not to effects of
the other genetic factors in the backgrounds of these mouse strains.
Indeed, the influence of strain background may have attenuated
the magnitude of the change in amyloid burden by the partial
reduction in RAP.
Whether modest reductions in LRP or SorLA/LR11 account
for the increased amyloid burden we have observed is unclear. In
previous studies, complete deficiency in SorLA/LR11 was shown
to cause a 30% increase in the secretion of mouse Ab40 and 42
[35]. More substantial reductions in SorLA/LR11 levels (80%) in
the frontal cortex of AD patients, without changes in LRP levels,
has been found to correlate with higher amyloid burden [35]. In
the study by Van Uden and colleagues of PDGF-APPInd mice
mated to RAP KO mice, increases in amyloid burden were
correlated with 80% reductions in the levels of mature LRP [27].
Collectively, these studies suggest that reductions in LRP and/or
SorLA/LR11 that are of a significantly greater magnitude than
found here produce significant changes in amyloidogenesis. We
conclude that either RAP possesses an activity that influences
amyloidogenesis in the absence of profound effects on LRP and
SorLA/LR11 maturation, or relatively modest reductions in the
levels of these proteins (separately or in combination) are sufficient
to cause significant changes in the rate of amyloid deposition in the
APPswe/PS1dE9 model.
The genetic association of LRP and SorLA/LR11, and their
ligands, APOE, a2M, and APP, to AD indicates that these
membrane receptor proteins could play important roles in the
pathogenesis of AD. Previous studies provide evidence that LRP
has opposing effects on APP processing and Ab metabolism. LRP
can promote Ab production by altering the processing of APP
through interactions with the Kunitz protease inhibitor (KPI)
domain (APP751 or APP770) [36]. Although the APP695 isoform,
which lacks a KPI domain, can weakly bind to LRP through
cytoplasmic adaptor proteins, such as FE65 [37], it is not known
whether the processing of APP695 can be influenced by LRP.
LRP also functions in the catabolism of Ab peptides and it is
possible that modest reductions in LRP levels are sufficient to
diminish the rate of Ab clearance, which involves the binding of
Figure 1. Partially reducing RAP increases Ab deposition in the brains of APPswe/PS1dE9 mice. A). Silver staining reveals increased
amyloid deposition in the brains of [APPswe/PS1dE9](+/2)/RAP(+/2) mice as compared to the parental APPswe/PS1dE9 line 85 mice. B). Plot of the
results from counting amyloid plaques following procedures described in Methods. Each dot indicates the number of amyloid plaques on a section.
Six sections per animal were counted by two independent assessors that were blind to the genotype of the animals. Each section was counted 3
times by each assessor and averaged. Statistical analyses was conducted on the mean number of deposits for each animal [n=6 for APPswe/PS1dE9
mice and n=7 for the [APPswe/PS1dE9](+/2)/RAP(+/2) mice]. The statistical difference in amyloid burden between animals of the 2 genotypes was
estimated by 2-tailed t-test with equal variance (p,0.05).
doi:10.1371/journal.pone.0003159.g001
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LR11 has been shown to promote the trafficking of APP to
discrete intracellular compartments that result in decreased Ab
secretion [35]. Thus, reduced levels of SorLA/LR11 could
increase Ab production. Collectively, these studies suggest very
complicated inter-connected pathways by which these proteins
could influence APP processing and Ab metabolism. It is possible
that the combined effects of modest reductions in both LRP and
SorLA/LR11 could, by different mechanisms, alter the balance of
Ab production and clearance to increase the rate of amyloid
deposition. However, because the effects of partial RAP deficiency
in the levels of these two proteins is so modest, it is possible that
RAP may have the capacity to modulate amyloid deposition by
other, yet to be defined, pathways.
As outlined in the Introduction, our work replicates and extends
a previous study by van Uden and colleagues [28]. Despite the
potential caveats to the van Uden study that are described in the
Introduction, we seem to produce a similar result, which is
increased amyloid burden when RAP levels are decreased. In our
case, only partial reduction in RAP levels was sufficient to increase
amyloid deposition. Although we have similar outcomes to the van
Uden study, the mechanisms by which these effects occur could be
different. The J9 mice used by van Uden were PDGF-hAPPSwe/Ind
mice, which created by Mucke and colleagues [40]. The J9 model
utilizes a mini-APP gene that can produce all three isoforms of
APP: APP695, APP751 and APP770 [41]. Thus, based on the
discussion above, one prediction might have been for deficiency in
RAP to lead to diminished amyloid deposition because the
absence of LRP would reduce Ab production from APP751 and
770 splice variants. However, since amyloid burden increased in
RAP deficiency, it is possible that the loss of LRP slowed the
clearance of Ab, resulting in increased amyloid deposition. It is
also possible that lowering the levels of SorLA/LR11 by deleting
RAP may have contributed to the increase in Ab deposition.
In a direct test of the role of LRP in amyloidogenesis, transgenic
mice that overexpress an LRP-minireceptor, containing the
ligand-binding domain II of human LRP and the region
representing the transmembrane subunit including the full
cytoplasmic tail (mLRP2), were mated to PDAPP mice [24].
The authors reported 3-fold increases in LRP levels and found
Figure 2. Filter assay of amyloid burden in [APPswe/PS1dE9](+/2)/RAP(+/2) mice. A). Filter trap assays of tissue homogenates from 6
parental line 85 mice and 6 offspring that were APPswe/PS1dE9 positive and hemizygous for RAP was performed as described in Methods. Each
column contains a serial dilution of the sample. 300 mg total protein was loaded in the first well, followed by serial 2-fold dilutions. The [APPswe/
PS1dE9](+/2)/RAP(+/2) mice have about twice the amount of high molecular weight Ab burden as the parental line 85 mice at the same age (9
months). B). Quantification of signal intensity was measured as described in Methods across the entire range of dilutions for each group of mice. The
amount of high molecular weight ‘‘aggregated’’ Ab was found to be significantly higher in [APPswe/PS1dE9](+/2)/RAP(+/2) mice at 9 months as
compared to the parental APPswe/PS1dE9 animals of the same age (p values noted on graph).
doi:10.1371/journal.pone.0003159.g002
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LRP (1:1000) and monoclonal antibody anti-LR11 (1:1000; BD Biosciences, San Jose, CA). Protein concentration was determined by BCA. Each lane
contains 100 mg total protein. Genotypes of the mice are marked on the figure. B). Quantification of the intensity of the bands in panel A, using a Fuji
LAS-3000 imaging device and software provided by the manufacturer. Statistical comparisons of each protein in the two genotypes of interest
([APPswe/PS1dE9](+/2)/RAP(+/+) and [APPswe/PS1dE9](+/2)/RAP(+/2) were conducted on the raw quantitative data, which consisted of pixel values
for each protein band quantified. Two-tailed student t-Test with equal variance was used to estimate the probability that differences in the levels of
each protein, between genotypes, resulted from random chance (p values for each comparison are noted on the figure). Because the levels of each
protein were measured as lower in mice lacking one RAP allele, we chose to graph the data by setting the mean value for each protein in the
[APPswe/PS1dE9](+/2)/RAP(+/+) mice to 100, designated controls, and then graphing the values of mice lacking one RAP allele as a percent of the
controls. The data represent measures from 6 [APPswe/PS1dE9](+/2)/RAP(+/+) mice compared to 7 [APPswe/PS1dE9] (+/2)/RAP(+/2) mice (except
for measures of LR11 n=6 as one lane was unmeasurable). The two mice without APPswe/PS1dE9 transgenes were not included in measurements so
that the only difference between the two groups of animals analyzed was the number of functional RAP alleles.
doi:10.1371/journal.pone.0003159.g003
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PDAPP mice, but did not find evidence of a change in amyloid
loads in mice harboring both transgenes as compared to mice
harboring only the PDAPP transgene. If LRP directly affects
amyloidogenesis by mediating clearance of Ab peptides, then one
would have predicted that the above study would have produced
mice with lowered amyloid burden. However, the transgene
product was not full-length LRP and the transgene was not
expressed by its endogenous promoter. Additional study is clearly
required to clarify the role LRP in APP and Ab metabolism.
Mutant PS1 and LRP maturation
It has been reported that the levels of mature, endoproteoly-
tically cleaved, LRP in the murine nervous system are reduced
when AD associated mutants of PS1 (M146L or L286V, expressed
via the hamster prion protein gene promoter) are present [27].
Our expectation was that PS1dE9 (expressed via the mouse prion
protein gene promoter), which has a strong effect on APP
processing [33,42,43], would also affect LRP maturation.
However, our data do not provide evidence that this is the case.
Moreover, partial reduction of RAP with co-expression of PS1dE9
also has little impact on the levels of mature LRP. Thus, either the
PS1dE9 variant of PS1 does not have the same activity towards
LRP maturation as possessed by the M146L or L286V variants, or
some subtle difference in the expression pattern of the PS1
transgenes in the different mouse models modulates the effects.
Lethality in RAP(2/2) mice that co-express APPswe/
PS1dE9
The cause of lethality in RAP(2/2) mice that harbor the
APPswe/PS1dE9 transgene is not clear. The overall number of
RAP(2/2) mice, regardless of the presence of the APPswe/
PS1dE9 transgene, that were identified in the genotyping of
weaning age mice was lower than expected (Table 1). Initially, we
suspected that the poor survival of [APPswe/PS1dE9](+/2)/
RAP(2/2) mice was due to a combined effect of RAP deficiency
and mutant PS1expression on LRP levels such that LRP levels
were lowered to a level below the threshold for survival.
Homozygous deletion of LRP is embryonic lethal [44]. However,
as noted above, LRP maturation in PS1dE9 mice was not affected
as significantly as reported in mice expressing other PS1 variants.
At present the basis for poor survival is unknown but it appears
that expression of PS1dE9 is implicated because others have not
noted that expression of mutant APP in a RAP null background
decreases survival [27].
Conclusions
It is clear from the literature that interactions between RAP and
LRP, between LRP and APP, and between LRP and APOE,
a2M, and Ab create a complicated network by which amyloido-
genesis might be regulated. RAP also regulates other members of
the LRP family, such as LRP1B [17], SorLA/LR11[45], LDL-R
and VLDL-R [46], which adds additional complexity to the
system. We find that APPswe/PS1dE9 mice with partial reduction
in RAP showed significant amyloid burden increases with modest
to slight reductions in the levels of mature SorLA/LR11 and LRP.
Although it is possible that modest reductions in SorLA/LR11 and
LRP act in concert to alter the processing or clearance of Ab,i ti s
also possible that RAP has more direct effects on APP processing
or the clearance of Ab peptides. Overall, RAP could be viewed as
either directly or indirectly influencing multiple processes that
modulate Alzheimer-type amyloidogenesis.
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